Advances in Clinical Chemistry and Laboratory Medicine (eBook)

lt;!doctype html public "-//w3c//dtd html 4.0 transitional//en">

Harald Renz, University of Marburg, Germany; Rudolf Tauber, Charité, Berlin, Germany.

Harald Renz, Universität Marburg; Rudolf Tauber, Charité, Berlin.

Preface 5
1 Plenary Articles 19
1.1 Proteomics strategies targeting biomarkers for cardiovascular disease 21
1.2 Influence of pre-examination aspects on result’s validity – are ISO 15189 requirements sufficient and clear? 27
1.3 Posttranslational modifications in tumor diagnosis 30
1.4 Chronic inflammatory disease: a result of complex gene-environment interaction 34
2 Symposium Articles 39
2.1 Component-array technology diagnostics: a step forward in the study of the sensitization profile of allergic patients 41
2.2 Pediatric metabolic syndrome: pathophysiology and molecular mechanisms 44
2.3 Urinary 8-hydroxydeoxyguanosine as a biomarker of microangiopathic complications in type 2 diabetic patients 48
2.4 Biological variation data: the need for appraisal of the evidence base 53
2.5 RecoveryELISA - a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy 56
2.6 Genotypic prediction of HIV-1 tropism from plasma and peripheral blood mononuclear cells in the clinical routine laboratory 60
2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size 64
2.8 Serological markers of gastric pathology 68
2.9 BNP as a biomarker of cardiac impairment in neonates with congenital heart diseases 72
2.10 Are 25-hydroxyvitamin D assays fit for purpose? 76
2.11 Update on multiple sclerosis 79
2.12 Microalbuminuria and urinary retinol binding protein as markers of subtle renal injury in visceral leishmaniasis: sensitivity, specificity and predictive values of the immunoturbidimetric technique 83
2.13 Occult hepatitis B virus infection: diagnosis and significance 86
2.14 Unmet needs in chronic kidney disease testing 90
2.15 Towards a national chronic kidney disease testing program 93
2.16 Biochemistry and metabolism of vitamin D 96
2.17 Diagnostics of thalassemia 100
2.18 The specific roles of assessors during accreditation 103
2.19 Laboratory diagnosis of hereditary spherocytosis 106
2.20 Quantification of blood folate forms using stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry 109
2.21 Evaluation of the new Marburg cerebrospinal fluid model with human spondylopathies 113
2.22 E-learning experiences of national societies of clinical chemistry and laboratory medicine 117
2.23 The experience of Médecins Sans Frontières in laboratory medicine in resource-limited settings 120
2.24 Screening, identifying, and quantifying small molecules by hyphenated mass spectrometry in toxicology and drug monitoring – an update 126
2.25 Analytical quality in the Latin America area 129
2.26 Standardization in molecular diagnostics: definitions and uses of nucleic acid reference materials 134
2.27 Profiling of antiphospolipid antibodies – association with cerebrovascular events in APS 138
2.28 Plasma levels of soluble CD30 and CD40L in pediatric patients after liver transplantation 142
2.29 Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST presepsin 146
2.30 Diagnostic workup of primary aldosteronism 152
2.31 What should the clinical laboratory and the toxicologist-pharmacologist offer the poisoned patient? 156
2.32 Novel aspects of von Willebrand factor – platelet glycoprotein IB interaction and signaling 160
2.33 Medical emergencies: what is the laboratory’s role? 161